Autologous peripheral blood progenitor cell (PBPC) transplantation is the treatment of choice for selected myeloma patients. However, tumor cells contaminating the apheresis product are a potential source of relapse. Here we report a sequential purging strategy targeting mature and immature clonogenic myeloma cell populations in the autograft.
Abstract
Autologous peripheral blood progenitor cell (PBPC) transplantation is the treatment of choice for selected myeloma patients. However, tumor cells contaminating the apheresis product are a potential source of relapse. Here we report a sequential purging strategy targeting mature and immature clonogenic myeloma cell populations in the autograft.
Thawed PBPC products of myeloma patients were treated with rituximab to kill CD138 
Introduction
The failure of CD34 + selection to effectively purge tumor cells demonstrates the need for the development of new purging strategies, specifically ones that target relevant tumor cells. CD138 is expressed by normal and differentiated myeloma plasma cells. The proteosome inhibitor bortezomib can be used to kill cells that express CD138 (11-12).
However, a separate myeloma population that does not express CD138 exists. It is a highly clonogenic immature cell population with a CD138 Therefore, we hypothesized that a purging strategy for PBPC products from patients with myeloma that used a combination of rituximab and bortezomib and a period of ex vivo co-culture with MSC might prove effective by killing mature CD138 + and immature CD138 -20 + myeloma cells, while preserving (and possibly increasing) the content of normal hematopoietic progenitors. Here we report the development of this multi-step strategy.
MATERIALS AND METHODS

Cell Lines
Myeloma cell lines RPMI-8226, ARP-1 and NCI-H929 were obtained from American Type Culture Collection (Manassas, VA) and cultured at 37 o C, 5% CO 2 in air, fully humidified atmosphere in RPMI medium (Gibco, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone, Logan, UT, USA).
Initial Treatment of Peripheral Blood Progenitor Cell (PBPC) products
Cryopreserved PBPC products were obtained from G-CSF-mobilized normal donors (N=4) and myeloma patients (N=16) in accordance with a University of Texas M. D.
Anderson Institutional Review Board (IRB)-approved protocol. All patients and donors gave their informed consent for these experiments.
Myeloma PBPC products were thawed in the presence of a DNAse to reduce aggregate formation (55 U/ml Benzonase, EMD Chemicals, Inc., Gibbstown, NJ) and washed in Combined Rituximab and Bortezomib Treatment of PBPC from myeloma patients.
Following single drug optimization studies, CD138 depleted cells or total PBPC from myeloma patient samples were incubated with 20 µg/ml rituximab in the presence of 10% human AB serum (source of compliment) for 24 hours with Bortezomib (20 nM) added for the last 16 hours of incubation.
Ex Vivo Culture Conditions
After drug treatment, cells were washed and co-cultured for 7 days at 37 
Viability Assay
PCR
Clonality Assay
The QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) was used to extract DNA from 10 6 cell aliquots collected at appropriate points throughout the purging procedure. 
Colony-Forming Cell (CFC) Assay
The number of CFC was assessed in unmanipulated PBPC samples and after CD138
depletion, rituximab and bortezomib drug treatment and ex vivo expansion. Cells were plated at 3,000-10,000 cells in 1 ml of methylcellulose medium containing hematopoietic 
RESULTS
Effect of Bortezomib on Myeloma Cell Lines and Normal CD34 + PBPC.
The effect of bortezomib (2.5-160 nM) was investigated on RPMI-8226 and ARP-1 myeloma cell lines ( Fig. 2A and 2B ) and on normal CD34 + isolated from 3 healthy donor PBPC (Fig. 2C) . A 24-hour incubation with bortezomib at 80 nM induced 80-90% growth inhibition in the myeloma cell lines ( Fig. 2A and 2B ), however, and it also markedly inhibited (80%) the growth of normal CD34 + cells (Fig. 2C ). 
Impact of Purging on Normal Hematopoietic Progenitor Cells
With the efficacy of this purging strategy against tumor cells confirmed both by FACS ( Fig 4A) and PCR (Fig 4B) , the impact of the process on normal HPC was also + and CFC numbers from those originally input (Fig 5A and B) .
MACS depletion of CD138 + cells does not improve efficacy of purging.
With the demonstrated efficacy of bortezomib against the CD138 + cells and with the goal of simplifying the purging procedure and facilitating its clinical application, we removed the MACS CD138 + cell depletion step. To this end, 4 myeloma PBPC were treated with bortezomib and rituximab without prior CD138 + MACS depletion to determine the efficacy of this approach. Further, in these 4 cases, the myeloma patients had been previously treated with bortezomib, allowing us to better mimic the clinical situation where the majority of myeloma patients will have received bortezomib as standard of care. The removal of the CD138 + MACS depletion step did not impact the efficacy of the tumor purging achieved as shown by representative flow cytometric (Fig. 6 A-C) and PCR data (Fig. 6 D-F) . Although an approximate 50% and 30% reduction in TNC and CD34 + numbers, respectively was still observed after treatment with bortezomib and rituximab (in the absence of the MAC depletion), the subsequent 14-day period of ex vivo culture produced an approximate 12 and 8-fold increase in TNC and CD34 + numbers, respectively, from those originally input (Fig. 7) .
Discussion
Our results indicate that incubation of PBPC products of myeloma patients with rituximab and bortezomib followed by a period of ex vivo culture markedly depletes CD138 + and 
The availability of normal allogeneic MSC (predisposed to support normal hematopoiesis) rather than having to use autologous MSC derived from the myeloma patient for the co-culture step may be an important benefit. MSC from myeloma patients present a distinct genetic and phenotypic profile that appears to favor the survival and proliferation of myeloma cells. As such they might be predisposed to support the survival and proliferation of myeloma cells during co-culture, The use of normal MSC might be, at least in part, responsible for the continued purging of tumor cells and support of normal HPC observed in our procedure (32) (33) (34) (35) (36) (37) .
In addition, our experiments show that the MACS CD138 + cell depletion, first thought to be an important component of the purging process, does not contribute substantially to its efficacy. The removal of the MACS CD138 + depletion step will facilitate the clinical development of our purging procedure.
We appreciate that these data need to be interpreted with caution. Firstly, while most of the CD138 + plasma cells detectable in the bone marrow of myeloma patients are malignant (as opposed to earlier stages of the myeloma transformation process) (38), we did not perform multi-parametric flow cytometry. This might reveal disease-specific aberrant phenotypes and allow differentiation between tumor and normal plasma cells present in these patients (39) . Therefore, while the eradication of the CD138 + population by the use of bortezomib markedly depletes the malignant plasma cells it also likely depletes the small number of normal plasma cells present. Any adverse impact of such a depletion on post-transplant immunity might only be ascertained in a clinical trial. Secondly, while the purging process appeared to successfully deplete mature and immature components of the disease, it is possible that tumor cells were still present in the end product, albeit at levels below the levels of detection of flow cytometry and PCR.
Evidence for potential residual tumor might only become apparent during in vivo studies.
While an in vivo mouse model is currently in development, it might ultimately fall to a clinical trial to address this concern.
In conclusion, our sequential purging strategy, including rituximab and bortezomib treatment followed by ex vivo culture, appears to effectively deplete mature and immature myeloma cells present in PBPC from myeloma patients. Further, in addition to effective tumor purging, another benefit of this procedure is the expansion of normal HPC. This we hypothesize will provide a tumor-free graft with a high hematopoietic reserve which should ultimately perform well in a transplant setting. A clinical trial is planned to determine the safety of this purging strategy in myeloma patients. Flow cytometric (Fig. 6 A-C) and PCR analyses (Fig 6 D-F 
